Bioventus Q1 Revenue $132.09M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Reports Q1 revenue $132.09M, consensus $129.9M. "Our team delivered a strong start to 2026, driven by continued momentum in our core businesses and disciplined execution across our commercial and operational priorities," said Rob Claypoole, Bioventus President and Chief Executive Officer. "We are focused on delivering above market growth for the year, while maintaining peer-leading gross margins, which allows us to reinvest in our multiple growth drivers, expand profitability, and generate strong cash flow, positioning Bioventus to deliver sustainable long-term shareholder value."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BVS
Wall Street analysts forecast BVS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.280
Low
13.00
Averages
14.00
High
15.00
Current: 9.280
Low
13.00
Averages
14.00
High
15.00
About BVS
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Conexeu Sciences Inc. Begins Trading on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking a significant advancement for the preclinical-stage company centered around its CXU™ bioregenerative platform, which is expected to attract more investment for product development.
- Innovative Platform: The CXU™ is a patented bioregenerative extracellular matrix designed to restore soft tissue lost due to injury, aging, and GLP-1-related weight loss, with its first product, Ten Minute Tissue™, demonstrating enhanced healing dynamics and a low inflammatory profile in preclinical studies, potentially garnering significant market interest.
- Market Outlook: Conexeu enters a public market that is showing genuine commercial momentum, with competitors like Integra LifeSciences and Bioventus exceeding expectations in recent earnings reports, indicating strong demand in the regenerative medicine sector, and the listing is likely to enhance Conexeu's market share.
- Strategic Positioning: The listing not only provides Conexeu with the opportunity for capital formation but also enables the advancement of the CXU™ platform across multiple product lines, with plans to submit a 510(k) application in early 2027, further solidifying its position in the regenerative medicine field.
See More
Conexeu Sciences Inc. Successfully Debuts on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking its entry into public markets as a regenerative tissue platform company, which is expected to drive business growth in wound care and aesthetic medicine sectors.
- Platform Advantage: The company's CXU™ extracellular matrix platform is designed to scale across multiple markets without reformulation, a structural advantage that sets it apart from early-stage regenerative medicine companies and may lay the groundwork for future market share expansion.
- Innovative Reconstruction Method: Conexeu's B.R.E.A.S.T.™ matrix is a 3D bioprinted scaffold designed to support the body's own tissue regeneration rather than serve as a permanent implant, representing a potential paradigm shift for over 100,000 U.S. women undergoing mastectomies annually.
- Intellectual Property Protection: Conexeu holds issued patents across the U.S., E.U., Japan, and Australia with no royalty or licensing obligations, providing the freedom to expand into new indications and potentially accelerating its 510(k) submission process.
See More
Bioventus (BVS) Q1 2026 Earnings Transcript
See More
Bioventus Q1 2026 Earnings Call Highlights
- Strong Financial Performance: Bioventus reported Q1 revenue of $132 million, a 7% increase year-over-year, with adjusted earnings per share at $0.15, demonstrating successful execution of growth strategies that are likely to boost shareholder confidence and market performance.
- Guidance Upgraded for 2026: Management raised the adjusted EPS forecast to between $0.75 and $0.79 and cash flow expectations to $84 million to $89 million, reflecting confidence in future growth while maintaining a revenue target of $600 million to $610 million, indicating robust financial planning.
- Investment in Growth Drivers: The company increased investments in PNS, PRP, Ultrasonics, and international segments, particularly with the addition of new General Manager Megan Rosengarten, aiming to accelerate business expansion and provide strong support for future revenue growth.
- Profitability and Cash Flow Management: While anticipating margin fluctuations between quarters, management plans to maintain an adjusted EBITDA margin around 20%, emphasizing the importance of robust cash flow management to support the company's long-term strategic development.
See More
Bioventus Q1 Earnings Exceed Expectations
- Strong Earnings Performance: Bioventus reported a Q1 non-GAAP EPS of $0.15, beating expectations by $0.08, indicating a significant improvement in profitability and enhanced competitive positioning in the market.
- Stable Revenue Growth: The company achieved Q1 revenue of $132.1 million, reflecting a 6.6% year-over-year increase and exceeding market expectations by $2.2 million, demonstrating sustained demand for its products and robust business development.
- Significant Cash Flow Improvement: Operating cash flow reached $8.9 million, an increase of $28.3 million compared to a $19.3 million outflow in the prior year, showcasing enhanced cash management and operational efficiency, which strengthens future investment capabilities.
- Optimistic Outlook Guidance: Bioventus raised its non-GAAP EPS and cash flow guidance while reaffirming its revenue guidance for 2026, targeting sales between $600 million and $610 million, reflecting the company's confidence in future growth and commitment to strategic investments.
See More
Bioventus Reports 7% Revenue Growth in Q1
- Significant Revenue Growth: Bioventus reported global revenue of $132.1 million for Q1, marking a 7% increase driven by sustained growth across its diverse product portfolio, indicating strong market performance.
- Improved Profitability: The company achieved GAAP earnings of $0.04 per share in Q1, reversing a loss of $0.04 per share in the prior year, reflecting successful operational efficiency and cost control measures.
- Strong Cash Flow: Operating cash flow reached $8.9 million, a substantial increase of $28.3 million compared to a cash outflow of $19.3 million in the previous year, demonstrating significant improvements in cash management and profitability.
- Optimistic Outlook: Bioventus raised its guidance for 2026 adjusted EPS and cash from operations, expecting adjusted EPS to reach between $0.75 and $0.79, showcasing the company's confidence in future growth.
See More
Conexeu Sciences Inc. Begins Trading on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking a significant advancement for the preclinical-stage company centered around its CXU™ bioregenerative platform, which is expected to attract more investment for product development.
- Innovative Platform: The CXU™ is a patented bioregenerative extracellular matrix designed to restore soft tissue lost due to injury, aging, and GLP-1-related weight loss, with its first product, Ten Minute Tissue™, demonstrating enhanced healing dynamics and a low inflammatory profile in preclinical studies, potentially garnering significant market interest.
- Market Outlook: Conexeu enters a public market that is showing genuine commercial momentum, with competitors like Integra LifeSciences and Bioventus exceeding expectations in recent earnings reports, indicating strong demand in the regenerative medicine sector, and the listing is likely to enhance Conexeu's market share.
- Strategic Positioning: The listing not only provides Conexeu with the opportunity for capital formation but also enables the advancement of the CXU™ platform across multiple product lines, with plans to submit a 510(k) application in early 2027, further solidifying its position in the regenerative medicine field.
See More
Conexeu Sciences Inc. Successfully Debuts on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking its entry into public markets as a regenerative tissue platform company, which is expected to drive business growth in wound care and aesthetic medicine sectors.
- Platform Advantage: The company's CXU™ extracellular matrix platform is designed to scale across multiple markets without reformulation, a structural advantage that sets it apart from early-stage regenerative medicine companies and may lay the groundwork for future market share expansion.
- Innovative Reconstruction Method: Conexeu's B.R.E.A.S.T.™ matrix is a 3D bioprinted scaffold designed to support the body's own tissue regeneration rather than serve as a permanent implant, representing a potential paradigm shift for over 100,000 U.S. women undergoing mastectomies annually.
- Intellectual Property Protection: Conexeu holds issued patents across the U.S., E.U., Japan, and Australia with no royalty or licensing obligations, providing the freedom to expand into new indications and potentially accelerating its 510(k) submission process.
See More
Bioventus (BVS) Q1 2026 Earnings Transcript
See More
Bioventus Q1 2026 Earnings Call Highlights
- Strong Financial Performance: Bioventus reported Q1 revenue of $132 million, a 7% increase year-over-year, with adjusted earnings per share at $0.15, demonstrating successful execution of growth strategies that are likely to boost shareholder confidence and market performance.
- Guidance Upgraded for 2026: Management raised the adjusted EPS forecast to between $0.75 and $0.79 and cash flow expectations to $84 million to $89 million, reflecting confidence in future growth while maintaining a revenue target of $600 million to $610 million, indicating robust financial planning.
- Investment in Growth Drivers: The company increased investments in PNS, PRP, Ultrasonics, and international segments, particularly with the addition of new General Manager Megan Rosengarten, aiming to accelerate business expansion and provide strong support for future revenue growth.
- Profitability and Cash Flow Management: While anticipating margin fluctuations between quarters, management plans to maintain an adjusted EBITDA margin around 20%, emphasizing the importance of robust cash flow management to support the company's long-term strategic development.
See More
Bioventus Q1 Earnings Exceed Expectations
- Strong Earnings Performance: Bioventus reported a Q1 non-GAAP EPS of $0.15, beating expectations by $0.08, indicating a significant improvement in profitability and enhanced competitive positioning in the market.
- Stable Revenue Growth: The company achieved Q1 revenue of $132.1 million, reflecting a 6.6% year-over-year increase and exceeding market expectations by $2.2 million, demonstrating sustained demand for its products and robust business development.
- Significant Cash Flow Improvement: Operating cash flow reached $8.9 million, an increase of $28.3 million compared to a $19.3 million outflow in the prior year, showcasing enhanced cash management and operational efficiency, which strengthens future investment capabilities.
- Optimistic Outlook Guidance: Bioventus raised its non-GAAP EPS and cash flow guidance while reaffirming its revenue guidance for 2026, targeting sales between $600 million and $610 million, reflecting the company's confidence in future growth and commitment to strategic investments.
See More
Bioventus Reports 7% Revenue Growth in Q1
- Significant Revenue Growth: Bioventus reported global revenue of $132.1 million for Q1, marking a 7% increase driven by sustained growth across its diverse product portfolio, indicating strong market performance.
- Improved Profitability: The company achieved GAAP earnings of $0.04 per share in Q1, reversing a loss of $0.04 per share in the prior year, reflecting successful operational efficiency and cost control measures.
- Strong Cash Flow: Operating cash flow reached $8.9 million, a substantial increase of $28.3 million compared to a cash outflow of $19.3 million in the previous year, demonstrating significant improvements in cash management and profitability.
- Optimistic Outlook: Bioventus raised its guidance for 2026 adjusted EPS and cash from operations, expecting adjusted EPS to reach between $0.75 and $0.79, showcasing the company's confidence in future growth.
See More
